Daiichi Sankyo Company, Limited Share Price Other OTC
Equities
DSNKY
US23381D1028
Pharmaceuticals
Sales 2024 | 1,602B 10.11B 843B | Sales 2025 * | 1,761B 11.12B 927B | Capitalization | 9,607B 60.65B 5,058B |
---|---|---|---|---|---|
Net income 2024 | 201B 1.27B 106B | Net income 2025 * | 186B 1.17B 97.68B | EV / Sales 2024 | 5.72 x |
Net cash position 2024 * | 556B 3.51B 293B | Net cash position 2025 * | 455B 2.87B 240B | EV / Sales 2025 * | 5.2 x |
P/E ratio 2024 |
45.6
x | P/E ratio 2025 * |
49
x | Employees | - |
Yield 2024 |
1.05% | Yield 2025 * |
1.14% | Free-Float | 97.04% |
Latest transcript on Daiichi Sankyo Company, Limited
Managers | Title | Age | Since |
---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/07/01 |
Hiroyuki Okuzawa
PSD | President | 61 | 01/17/01 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 01/19/01 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 01/19/01 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 01/07/01 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |